Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 May 14

PMID 35566737

Authors

Carlos J Toro-Huamanchumo

Jerry K Benites-Meza

Carlos S Mamani-Garcia

Diego Bustamante-Paytan

Abraham Edgar Gracia-Ramos

Cristian Diaz-Velez

Joshuan J Barboza

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic review.

Methods: Six databases were searched until March 2022 for studies assessing colchicine versus control in hospitalized patients with COVID-19. The primary outcome was mortality, and secondary outcome was length of hospitalization. Inverse variance and random effect meta-analyses were performed. The strength of evidence was assessed using GRADE.

Results: Nine studies (five randomized clinical trials (RCTs) and four non-randomized studies of intervention (NRSI); = 13,478). Colchicine did not reduce mortality in comparison with the standard of care in RCTs (RR 0.99; 95%CI 0.90 to 1.10; = 0.90); however, it did reduce mortality in NRSI studies (RR 0.45; 95%CI 0.26 to 0.77; = 0.02). In the analysis of RCTs, colchicine did not reduce the length of hospitalization in comparison with the standard of care (MD: -2.25 days; 95%CI: -9.34 to 4.84; = 0.15). Most studies were scored as having a high risk of bias. Quality of evidence was very low for primary and secondary outcomes.

Conclusion: Colchicine did not reduce the mortality and length of hospitalization in comparison with the standard of care in hospitalized patients with COVID-19. The published evidence is insufficient and of very low quality to recommend treatment in patients with COVID-19.

Citing Articles

Successful Treatment With High-Dose Colchicine of a 101-Year-Old Patient Diagnosed With COVID-19 After an Emergency Cholecystectomy.

Bulanov D, Yonkov A, Arabadzhieva E, Mitev V Cureus. 2024; 16(6):e63201.

PMID: 39070405 PMC: 11277179. DOI: 10.7759/cureus.63201.

The role of colchicine in the management of COVID-19: a Meta-analysis.

Elshiwy K, Amin G, Farres M, Samir R, Allam M BMC Pulm Med. 2024; 24(1):190.

PMID: 38641775 PMC: 11031948. DOI: 10.1186/s12890-024-03001-0.

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials.

Ahmad Cheema H, Jafar U, Shahid A, Masood W, Usman M, Hermis A BMJ Open. 2024; 14(4):e074373.

PMID: 38631824 PMC: 11029412. DOI: 10.1136/bmjopen-2023-074373.

Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.

Shafaghat Z, Ghomi A, Khorramdelazad H, Safari E Inflammopharmacology. 2023; 31(6):3005-3020.

PMID: 37805959 DOI: 10.1007/s10787-023-01344-4.

Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses.

Danjuma M, Sayed R, Aboughalia M, Hassona A, Elsayed B, Elshafei M Heliyon. 2023; 9(10):e20155.

PMID: 37767472 PMC: 10520783. DOI: 10.1016/j.heliyon.2023.e20155.

References

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View

Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G . Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med. 2020; 9(9). PMC: 7565543. DOI: 10.3390/jcm9092961. View

Sandhu T, Tieng A, Chilimuri S, Franchin G . A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. Can J Infect Dis Med Microbiol. 2020; 2020:8865954. PMC: 7588830. DOI: 10.1155/2020/8865954. View

Ioannidis J, Haidich A, Pappa M, Pantazis N, Kokori S, Tektonidou M . Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001; 286(7):821-30. DOI: 10.1001/jama.286.7.821. View

Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R . Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs. 2020; 80(18):1929-1946. PMC: 7568461. DOI: 10.1007/s40265-020-01421-w. View

Tardif J, Bouabdallaoui N, LAllier P, Gaudet D, Shah B, Pillinger M . Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021; 9(8):924-932. PMC: 8159193. DOI: 10.1016/S2213-2600(21)00222-8. View

Golpour M, Mousavi T, Alimohammadi M, Mosayebian A, Shiran M, Navaei R . The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis. Int J Immunopathol Pharmacol. 2021; 35:20587384211031763. PMC: 8274088. DOI: 10.1177/20587384211031763. View

Nasiripour S, Zamani F, Farasatinasab M . Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?. J Clin Pharmacol. 2020; 60(7):828-829. PMC: 7283693. DOI: 10.1002/jcph.1645. View

10.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

11.

van Aert R, Jackson D . Multistep estimators of the between-study variance: The relationship with the Paule-Mandel estimator. Stat Med. 2018; 37(17):2616-2629. PMC: 6055723. DOI: 10.1002/sim.7665. View

12.

Nuki G . Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008; 10(3):218-27. DOI: 10.1007/s11926-008-0036-3. View

13.

Elshafei M, El-Bardissy A, Khalil A, Danjuma M, Mubasher M, Abubeker I . Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis. Eur J Clin Invest. 2021; 51(9):e13645. PMC: 8420434. DOI: 10.1111/eci.13645. View

14.

Lopes M, Bonjorno L, Giannini M, Amaral N, Menezes P, Dib S . Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021; 7(1). PMC: 7868202. DOI: 10.1136/rmdopen-2020-001455. View

15.

Corral P, Corral G, Diaz R . Colchicine and COVID-19. J Clin Pharmacol. 2020; 60(8):978. PMC: 7300998. DOI: 10.1002/jcph.1684. View

16.

Diaz R, Orlandini A, Castellana N, Caccavo A, Corral P, Corral G . Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2021; 4(12):e2141328. PMC: 8717104. DOI: 10.1001/jamanetworkopen.2021.41328. View

17.

Nawangsih E, Kusmala Y, Rakhmat I, Handayani D, Juliastuti H, Wibowo A . Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression. Int Immunopharmacol. 2021; 96:107723. PMC: 8075849. DOI: 10.1016/j.intimp.2021.107723. View

18.

Absalon-Aguilar A, Rull-Gabayet M, Perez-Fragoso A, Mejia-Dominguez N, Nunez-Alvarez C, Kershenobich-Stalnikowitz D . Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). J Gen Intern Med. 2021; 37(1):4-14. PMC: 8577644. DOI: 10.1007/s11606-021-07203-8. View

19.

Della-Torre E, Della-Torre F, Kusanovic M, Scotti R, Ramirez G, Dagna L . Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020; 217:108490. PMC: 7261351. DOI: 10.1016/j.clim.2020.108490. View

20.

Deftereos S, Siasos G, Giannopoulos G, Vrachatis D, Angelidis C, Giotaki S . The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol. 2020; 61(1):42-45. PMC: 7194546. DOI: 10.1016/j.hjc.2020.03.002. View